Toward depression remission: balancing efficacy and tolerability.
Emerging research has found that different neurotransmitters play roles in the regulation of depressive symptomatology and adverse events associated with antidepressant treatment. Residual depressive symptoms and adverse events can lead to noncompliance and the discontinuation of treatment. Several approaches may help clinicians address residual symptoms and tolerability issues in patients with depression.